← Leaderboards
Paul J Shami
University Of Utah
$3,671,592
Attributed
$4,465,007
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,465,007 · 5
By mechanism
R01$3,274,466 · 3
R44$1,190,122 · 1
M01$419 · 1
Top collaborators
- Thomas Preston Kennedy3 shared
- Gregory John Johnson2 shared
- Sudhir Sahasrabudhe1 shared
Most similar at University Of Utah
Same institution · by research overlap
- William L. Carroll$23,653,738
- Jonathan Eric Constance$2,718,439
- Carol S Bruggers$122,859
- Thomas J. O'Hare$1,289,037
- Saveez Saffarian$2,826,902
Others in their field
Top investigators on “Nitric Oxide”
- Solomon H Snyder · Johns Hopkins University$33,003,131
- Jay Louis Zweier · Ohio State University$27,671,715
- Stuart A Lipton · Burnham Institute For Medical Research$26,301,120
- Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru$24,661,240
- Jonathan S. Stamler · Case Western Reserve University$24,571,968
- William C. Sessa · Yale University$21,022,028
Research focus
Nitric OxidePharmaceutical PreparationsHalf-LifeIn VivoNanoscaleMalignant NeoplasmsMicellesDrug DesignFamilyGlutathione S-TransferaseDinitrophenylDiazeniumdiolateLibrariesLeukemia, Myelocytic, AcuteNational Cancer InstituteLeadCancer CellApoptosisCollaborationsCancer TherapyAqueousGlutathioneDesignPre-Clinical
Grant awards (14)
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer$142,814
R44 · FY2014 · CA
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer$927,566
R44 · FY2012 · CA
Development of JS-K as an anti-leukemic agent$302,919
R01 · FY2012 · CA · contact PI
Development of JS-K as an anti-leukemic agent$302,919
R01 · FY2011 · CA · contact PI
Development of JS-K as an anti-leukemic agent$312,288
R01 · FY2010 · CA · contact PI
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer$119,742
R44 · FY2010 · CA
Development of JS-K as an anti-leukemic agent$1,063,969
R01 · FY2009 · CA · contact PI
Development of JS-K as an anti-leukemic agent$312,288
R01 · FY2009 · CA · contact PI
Development of JS-K as an anti-leukemic agent$311,769
R01 · FY2008 · CA · contact PI
ROLE OF NITRIC OXIDE IN MYELODYSPLASTIC SYNDROMES$419
M01 · FY2005 · RR
GENETIC TARGETS OF NITRIC OXIDE IN LEUKEMIA CELLS$207,813
R01 · FY2004 · CA
GENETIC TARGETS OF NITRIC OXIDE IN LEUKEMIA CELLS$207,813
R01 · FY2003 · CA
GENETIC TARGETS OF NITRIC OXIDE IN LEUKEMIA CELLS$207,813
R01 · FY2002 · CA
NO, GUANYLATE CYCLASE AND IMMUNOTHERAPY OF CANCER$44,875
R01 · FY2000 · CA